Innovative Intermittent Preventive Treatment Approaches to Reduce Malaria Burden in School-age Children in Burkina Faso
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This will be an open label cluster randomized study with two active intervention and one
control arm. A cluster will be defined as a selected village. One district implementing
seasonal malaria chemoprevention (SMC) will be selected, and six villages will be randomly
selected in this district. These six villages will be randomly allocated to each of the three
study arms; 1) Arm 1 will receive IPTsc with sulphadoxine-pyrimethamine plus amodiaquine
(SPAQ); and 2) Arm 2 will receive dihydroartemisinin-piperaquine (DP) plus Ivermectin (IVM),
all given monthly during the transmission season and 3) Control Arm which will have standard
malaria control measures including case management and vector control measures as applicable.
Phase:
Phase 3
Details
Lead Sponsor:
Malaria Consortium
Treatments:
Amodiaquine Artenimol Fanasil, pyrimethamine drug combination Ivermectin Piperaquine Pyrimethamine Sulfadoxine